Union Minister of State for Science and Technology, Dr Jitendra Singh gave the award for the successful commercialization of indigenous technology on National Technology Day 2022
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
The new hospital is expected to open by March'24
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
Subscribe To Our Newsletter & Stay Updated
